HUNT VALLEY, Md.--(BUSINESS WIRE)--May 3, 2006--CepTor Corporation (OTCBB:CEPO - News), a development-stage biopharmaceutical company focusing on cell-targeted therapeutic products for neuromuscular and neurodegenerative diseases, announced today that it is exploring various strategic alternatives to enhance shareholder value, including the possible sale or merger of the Company. CepTor Corporation has retained Oppenheimer & Co. as its strategic advisor to assist in this effort. The Company stated that there could be no assurance that this process will result in any specific transaction.
